ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01010542
Recruitment Status : Terminated (See termination reason in detailed description.)
First Posted : November 10, 2009
Last Update Posted : January 6, 2017
Sponsor:
Information provided by (Responsible Party):
Pfizer

November 6, 2009
November 10, 2009
January 6, 2017
December 2009
May 2011   (Final data collection date for primary outcome measure)
To assess the clinical activity of single SC (subcutaneous) dose of ILV-095 in subjects with psoriasis using the PASI (Psoriasis Area and Severity Index) score, the target lesion score and the PGA (Physician global assessment of psoriasis) score. [ Time Frame: 56 days for each treatment group ]
Same as current
Complete list of historical versions of study NCT01010542 on ClinicalTrials.gov Archive Site
To provide safety, tolerability, PK, PD and immunogenicity profiles of a single dose of ILV-095 in subjects with psoriasis using, adverse event collection, injection site reaction, actual times of sample collection and IL-22 analysis. [ Time Frame: 56 days for each treatment group ]
Same as current
Not Provided
Not Provided
 
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis. Another purpose of the study is to observe how the drug enters the blood and tissues over time, how the body breaks down the drug and whether or not the body will develop an immune reaction (sensitivity) to the drug.
B1991002 study is a phase 1 adaptive design study which terminated on 14Mar2011. Regular analyzes of psoriasis assessments conducted per the statistical plan indicate that even if every patient enrolled for the rest of the study respond (up to 23 additional subjects), the study can not meet its primary efficacy endpoint. Pfizer Inc. has terminated the trial and clinical team is asking all clinical investigators to continue collecting safety, pharmacokinetics and pharmacodynamics data until the last subject last visit for all subjects who received test article. Last Subject Last Visit occurred 20May2011.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Plaque Psoriasis
  • Drug: ILV-095 300 mg in a 4 to 1 ratio
    Single dose of ILV-095 300 mg
  • Drug: ILV-095 300 mg in a 4 to 1 ratio
    Single dose of Placebo
  • Active Comparator: ILV-095
    Intervention: Drug: ILV-095 300 mg in a 4 to 1 ratio
  • Placebo Comparator: placebo
    Intervention: Drug: ILV-095 300 mg in a 4 to 1 ratio
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
39
0
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Sexually active men or women must agree to use a medically acceptable form of contraception during the study and continue it for 16 weeks after investigational product administration.
  • Negative urine pregnancy test result for all women.
  • Body mass index (BMI) >=18 kg/m2 and body weight >=50 kg. BMI is calculated by taking the subject's weight, in kilograms, divided by the square of the subject's height, in meters, at screening: BMI = weight (kg)/(height [m]).
  • Must meet the following criteria for disease activity, at screening and/or at study entry (subjects who washout from prior therapy may not meet this level of disease activity at screening but must before being entered into the study).
  • Must have stable moderate to severe chronic plaque psoriasis covering >=15% of body surface area and be a candidate for systemic therapy or phototherapy.
  • Psoriasis Area Severity Index (PASI) score of >11.
  • Physician Global Assessment (PGA) of psoriasis score >=3.
  • Target lesion score >=6 based on the physician rating of selected sites for erythema, plaque elevation and scaling, with a minimum of 2 on the plaque elevation score. A-12-point score will be used with a 1-4 scale for each domain. Target lesions should not be on the scalp, axillae, face, or groin.

Exclusion Criteria:

  • Presence or history of any disorder that may prevent the successful completion of the study.
  • Evidence of unstable clinically significant disease (eg, unstable cardiovascular, renal, respiratory, or psychiatric disease or any serious disorder that currently requires physician care).
  • Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.
  • Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
  • Presence of guttate, erythrodermic, or pustular psoriasis.
  • Active severe infections within 4 weeks before study day 1.
  • Systemic malignancy within the past 5 years including melanoma. Treated skin cancer (basal cell carcinoma or squamous cell carcinoma) is excluded.

Evidence of latent tuberculosis by purified protein derivative (PPD) screening. PPD screening should be performed according to local standards using the tuberculin skin test (TST). Any result >5mm is considered positive. Prior Bacillus Calmette-Guerin (BCG) should not be taken into account when interpreting a TST result. TST must be performed during the screening period unless one has been performed within the previous 3 months and the results are available.

Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT01010542
3226K1-1002
B1991002
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP